[Skip to Navigation]
Views 1,817
Citations 0
News From the Food and Drug Administration
November 5, 2019

PrEP Drug Is Approved for Some Patients but Not for Others

JAMA. 2019;322(17):1644. doi:10.1001/jama.2019.17814

A second drug has received approval as preexposure prophylaxis (PrEP) for HIV-1. The combination of emtricitabine and tenofovir alafenamide is indicated for men and transgender women who have sex with men. But the drug isn’t indicated for cisgender (those whose gender identity aligns with their birth sex) women because they weren’t included in an international clinical trial.